The gap-map: honest coverage, not marketing.
Across 10 tracked conditions, CBG has 0 with established or demonstrated human efficacy, 1 with any human data at all, and 1 with no primary evidence. The rest are preclinical or mechanistic only. This is the honest state of the evidence.
Every grade below traces to the gated, provenance-hashed evidence registry (the Evidence Grading Engine). Mechanism only = a receptor interaction is measured but no effect study exists. Preclinical only = animal/lab evidence, no human data. Early human data = a small/short trial exists, still graded Low. No primary evidence = our registry has no study supporting a CBG effect there. Where the evidence is thin, we say so. None of these statuses is a statement of benefit, and none of this is medical advice.
This map covers CBG only. CBDV, CBGa, CBGV, CBC, CBN and THCV each have their own monograph, and their conditions are not tracked here yet — a gap in this map, not a gap in the evidence. CBDV in particular has a completed randomised controlled trial whose primary endpoint was not met, which this map does not show: see the CBDV monograph.
Brain & nervous system.
Anxiety & stress
1 small, short (acute, single-dose) human trial (graded Low). Contradicting evidence in our registry: 2 preclinical animal studies. Animal studies do not consistently reproduce an anxiety-reducing effect — one found no effect and another reported an anxiety-increasing effect — so the preclinical picture is mixed and does not confirm a benefit. Reaching 'Demonstrated' would take, on top of what we already hold: one larger, controlled, non-acute human trial — or two independent human observational studies. No amount of further animal or laboratory work can raise it — only human data can.
Neuroinflammation
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: two animal (preclinical) effect studies from independent research groups, agreeing in direction — or one human trial of any size — including a small, short (acute / single-dose) one.
Neuroprotection (Huntington's disease)
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
Cardiovascular.
Blood pressure / cardiovascular
A receptor mechanism is measured, but no study has measured an actual effect here. Reaching 'Low' would take, on top of what we already hold: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
Digestive.
Appetite stimulation
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
Colorectal cancer (preclinical)
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
Inflammatory bowel disease (colitis)
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
Eyes.
Intraocular pressure (glaucoma)
Often attributed to CBG, but our verified registry holds NO primary study supporting it — and none arguing against it either. We hold no primary study either way, so the honest state is UNKNOWN, not disproven. Putting this on the evidence ladder at all (grade 'Low') would take: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
Immune & inflammatory.
Antibacterial (MRSA)
Evidence is 2 preclinical studies (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
Skin.
Skin
Only a proposed receptor mechanism in the knowledge graph — our registry holds no graded claim and no study of any kind here, so no effect has been measured. Putting this on the evidence ladder at all (grade 'Low') would take: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
A gap is not a promise.
Nothing on this page says CBG works for any of these conditions. It records what has and has not been studied, and what would have to be done before a grade could move. Catalogue in progress.
The cardiovascular entry above is mechanistic and safety-relevant, not a benefit claim. CBG shows potent α2-adrenoceptor agonism in vitro, and α2 agonists can lower blood pressure — but no study has measured an actual blood-pressure effect of CBG. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
This map is generated from the gated claims registry — grades are never re-graded here, and conditions with no primary evidence are shown rather than hidden. Gap-map built 2026-08-23. Every underlying study is browsable in the Research Library.